Recruiting

Deucravacitinib

Sponsor:

UCLA

Code:

NCT05858645

Conditions

Psoriasis Vulgaris

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

deucravacitinib

Study Details

Brief summary:

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Conditions

Psoriasis Vulgaris

Study ID

NCT05858645

Start date

Oct 1, 2023

Status verified date

Jun, 2026

Completion date

Jun, 2028

Anticipated

Primary completion date

Jun, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. 18 years of age or older
2. Patients with moderate-severe psoriasis (BSA >= 10%, PASI >=12, static Physician's Global Assessment (sPGA) 3 and above)

Exclusion Criteria:

1. taking systemic immunosuppressives in the last 12 weeks
2. pregnancy
3. severe immunodeficiency (either from genetic or infectious causes).
4. tuberculosis or other active serious infection
5. active systemic malignancy.
6. breast-feeding
7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Study Design

Enrollment

25 participants

Anticipated

Intervention Model

Single group

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: deucravacitinib treatment

treatment with deucravacitinib for 6 months

Interventions

deucravacitinib

Treatment with deucravacitinib, skin biopsy and blood analysis pre- and mid-treatment

Primary outcome measure

  • Change in Psoriasis Area and Severity Index (PASI) score [ Time Frame: pre-treatment, 4 months ]

Central Contacts and Locations

Central contacts

Raymond Cho, MD, PhD

415 575 0524rashes@ucsf.edu

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94115

Contacts

Ray Cho, MD, PhD

415-575-0524rashes@ucsf.edu

More Information

Sponsor

University of California, San Francisco

Last update posted

Jun 4, 2026

Last verified

Jun, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-06-04.